Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 9, December, p. 1457–1464

doi: 10.17219/acem/65068

Publication type: review

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Brain death-associated pathological events and therapeutic options

Paweł Chudoba1,A, Wojciech Krajewski2,C,D, Joanna Wojciechowska3,D, Dorota Kamińska4,E,F

1 Department of Vascular, General and Transplant Surgery, Wroclaw Medical University, Poland

2 Department of Urology and Oncological Urology, Wroclaw Medical University, Poland

3 Department and Clinic of Otolaryngology Head and Neck Surgery, Wrocław Medical University, Poland

4 Department and Clinic of Nephrology and Transplantation Medicine, Wroclaw Medical University, Poland

Abstract

Background. At present, organ transplantation is the most efficient treatment of end-stage failure of various organs, including the heart, lungs, pancreas, intestines, kidney, and liver. Despite the efforts to use organs from living donors or from donors after circulatory death, most of the organs are recovered from brain dead (BD) donors. Methods. The Medline and Web of Science databases were searched without time limit on November 2015 using the terms “brain dead donor” and “deceased donor” in conjunction with “transplantation”, “graft”, “organ”, “hemodynamic”, “hormonal“, or “management”. The search was limited to the English, Polish and Spanish literature. Articles that did not address the topics were excluded and the full text of the remaining articles was reviewed.
Results. It is well established that brain death is associated with a cascade of hemodynamic, inflammatory, and immunologic events that affect the outcome of transplanted organs. Proper management of the potential organ donor may help increase the supply of organs for transplantation. However, because there is a lack of good quality evidence, it is difficult to establish specific BD donor management guidelines.
Conclusion. In this paper we present a review of studies and literature concerning the detrimental impact of donor brain death on graft function. We present pathologic changes that take place after brain death, their influence on graft quality and therapeutic solutions to enhance transplanted organ function.

Key words

transplantation, brain dead donor, deceased donor, organ management

References (60)

  1. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med. 1995;333:333–336.
  2. Rowe TA, Huded J, McElroy L, Ladner DP, Lindquist LA. The evolution of living kidney donation and transplantation in older adults. J Am Geriatr Soc. 2015;63:2616–2620.
  3. Wijdicks EF, Varelas PN, Gronseth GS, Greer DM. Evidence-based guideline update: Determining brain death in adults. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74:1911–1918.
  4. Bos EM, Leuvenink HG, van Goor H, Ploeg RJ. Kidney grafts from brain dead donors: Inferior quality or opportunity for improvement? Kidney Int. 2007;72:797–805.
  5. Chen EP, Bittner HB, Kendall SW, Van Trigt P. Hormonal and hemodynamic changes in a validated animal model of brain death. Crit Care Med. 1996;24:1352–1359.
  6. Novitzky D, Cooper DK, Rosendale JD, Kauffman HM. Hormonal therapy of the brain-dead organ donor: Experimental and clinical studies. Transplantation. 2006;82:1396–1401.
  7. Taniguchi S, Kitamura S, Kawachi K, Doi Y, Aoyama N. Effects of hormonal supplements on the maintenance of cardiac function in potential donor patients after cerebral death. Eur J Cardiothorac Surg. 1992;6:96–102.
  8. Gelb AW, Robertson KM. Anaesthetic management of the brain dead for organ donation. Can J Anaesth. 1990;37:806–812.
  9. Minambres E, Rodrigo E, Ballesteros MA, et al. Impact of restrictive fluid balance focused to increase lung procurement on renal function after kidney transplantation. Nephrol Dial Transplant. 2010;25:2352–2356.
  10. Pennefather SH, Bullock RE, Dark JH. The effect of fluid therapy on alveolar arterial oxygen gradient in brain-dead organ donors. Transplantation. 1993;56:1418–1422.
  11. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet. 1996;348:1620–1622.
  12. Randell T, Orko R, Hockerstedt K. Peroperative fluid management of the brain-dead multiorgan donor. Acta Anaesthesiol Scand. 1990;34:592–595.
  13. Blasco V, Leone M, Antonini F, Geissler A, Albanese J, Martin C. Comparison of the novel hydroxyethylstarch 130/0.4 and hydroxyethylstarch 200/0.6 in brain-dead donor resuscitation on renal function after transplantation. Br J Anaesth. 2008;100:504–508.
  14. Schnuelle P, Berger S, de Boer J, Persijn G, van der Woude FJ. Effects of catecholamine application to brain-dead donors on graft survival in solid organ transplantation. Transplantation. 2001;72:455–463.
  15. Schnuelle P, Gottmann U, Hoeger S, et al. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: A randomized controlled trial. JAMA. 2009;302:1067–1075.
  16. Fontana J, Yard B, Stamellou E, et al. Dopamine treatment of brain-dead Fisher rats improves renal histology but not early renal function in Lewis recipients after prolonged static cold storage. Transplant Proc. 2014;46:3319–3325.
  17. de Backer D, Aldecoa C, Njimi H, Vincent JL. Dopamine versus norepinephrine in the treatment of septic shock: A meta-analysis. Crit Care Med. 2012;40:725–730.
  18. Stoica SC, Satchithananda DK, White PA, Parameshwar J, Redington AN, Large SR. Noradrenaline use in the human donor and relationship with load-independent right ventricular contractility. Transplantation. 2004;78:1193–1197.
  19. von Ziegler F, Helbig S, Kreissl N, Meiser B, Becker A, Kaczmarek I. Norepinephrine versus dopamine pretreatment of potential heart donors: Impact on long-term outcome. Ann Transplant. 2013;18:320–326.
  20. Sakagoshi N, Shirakura R, Nakano S, Taniguchi K, Miyamoto Y, Matsuda H. Serial changes in myocardial beta-adrenergic receptor after experimental brain death in dogs. J Heart Lung Transplant. 1992;11:1054–1058.
  21. Ryu HG, Jung CW, Lee HC, Cho YJ. Epinephrine and phenylephrine pretreatments for preventing postreperfusion syndrome during adult liver transplantation. Liver Transpl. 2012;18:1430–1439.
  22. Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation. 2003;75:482–487.
  23. Rech TH, Moraes RB, Crispim D, Czepielewski MA, Leitao CB. Management of the brain-dead organ donor: A systematic review and meta-analysis. Transplantation. 2013;95:966–974.
  24. Salim A, Vassiliu P, Velmahos GC, et al. The role of thyroid hormone administration in potential organ donors. Arch Surg. 2001;136:1377–1380.
  25. Rebolledo RA, van Erp AC, Ottens PJ, Wiersema-Buist J, Leuvenink HG, Romanque P. Anti-apoptotic effects of 3,3’,5-triiodo-L-thyronine in the liver of brain-dead rats. PLoS One. 2015;10:e0138749.
  26. Novitzky D, Mi Z, Sun Q, Collins JF, Cooper DK. Thyroid hormone therapy in the management of 63,593 brain-dead organ donors: A retrospective analysis. Transplantation. 2014;98:1119–1127.
  27. Donly BC, Edgar CD, Adamski FM, Tate WP. Frameshift autoregulation in the gene for Escherichia coli release factor 2: Partly functional mutants result in frameshift enhancement. Nucleic Acids Res. 1990;18:6517–6522.
  28. Joseph B, Aziz H, Pandit V, et al. Levothyroxine therapy before brain death declaration increases the number of solid organ donations. J Trauma Acute Care Surg. 2014;76:1301–1305.
  29. Dupuis S, Amiel JA, Desgroseilliers M, et al. Corticosteroids in the management of brain-dead potential organ donors: A systematic review. Br J Anaesth. 2014;113:346–359.
  30. Pinsard M, Ragot S, Mertes PM, et al. Interest of low-dose hydrocortisone therapy during brain-dead organ donor resuscitation: The CORTICOME study. Crit Care. 2014;18(4):R158.
  31. Dhar R, Cotton C, Coleman J, et al. Comparison of high- and low-dose corticosteroid regimens for organ donor management. J Crit Care. 2013;28:e111–117.
  32. Schuurs TA, Gerbens F, van der Hoeven JA, et al. Distinct transcriptional changes in donor kidneys upon brain death induction in rats: Insights in the processes of brain death. Am J Transplant. 2004;4:1972–1981.
  33. Callahan DS, Neville A, Bricker S, et al. The effect of arginine vasopressin on organ donor procurement and lung function. J Surg Res. 2014;186:452–457.
  34. Piazza O, Scarpati G, Rispoli F, Iannuzzi M, Tufano R, De Robertis E. Terlipressin in brain-death donors. Clin Transplant. 2012;26(6):E571–575.
  35. Martikainen TJ, Kurola J, Karja V, Parviainen I, Ruokonen E. Vasopressor agents after experimental brain death: Effects of dopamine and vasopressin on vitality of the small gut. Transplant Proc 2010;42:2449–2456.
  36. Meijer E, Bakker SJ, de Jong PE, et al. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation. 2009;88:561–567.
  37. Blasi-Ibanez A, Hirose R, Feiner J, et al. Predictors associated with terminal renal function in deceased organ donors in the intensive care unit. Anesthesiology. 2009;110:333–341.
  38. van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449–461.
  39. Mascia L, Pasero D, Slutsky AS, et al. Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation: A randomized controlled trial. JAMA. 2010;304:2620–2627.
  40. Youn TS, Greer DM. Brain death and management of a potential organ donor in the intensive care unit. Crit Care Clin. 2014;30:813–831.
  41. Joseph B, Khalil M, Pandit V, et al. Hypothermia in organ donation: A friend or foe? J Trauma Acute Care Surg. 2014;77:559–563.
  42. Kamarainen A, Virkkunen I, Tenhunen J. Hypothermic preconditioning of donor organs prior to harvesting and ischaemia using ice-cold intravenous fluids. Med Hypotheses. 2009;73:65–66.
  43. Niemann CU, Feiner J, Swain S, et al. Therapeutic hypothermia in deceased organ donors and kidney-graft function. N Engl J Med. 2015;373:405–414.
  44. Nijboer WN, Ottens PJ, van Dijk A, van Goor H, Ploeg RJ, Leuvenink HG. Donor pretreatment with carbamylated erythropoietin in a brain death model reduces inflammation more effectively than erythropoietin while preserving renal function. Crit Care Med. 2010;38:1155–1161.
  45. Bouzat P, Francony G, Thomas S, et al. Reduced brain edema and functional deficits after treatment of diffuse traumatic brain injury by carbamylated erythropoietin derivative. Crit Care Med. 2011;39:2099–2105.
  46. Cicora F, Stringa P, Guerrieri D, et al. Amelioration of renal damage by administration of anti-thymocyte globulin to potential donors in a brain death rat model. Clin Exp Immunol. 2012;169:330–337.
  47. Cicora F, Stringa P, Guerrieri D, et al. Evaluation of histological damage of solid organs after donor preconditioning with thymoglobulin in an experimental rat model. Transpl Immunol. 2013;28:203–205.
  48. Carlessi R, Lemos NE, Dias AL, et al. Exendin-4 attenuates brain death-induced liver damage in the rat. Liver Transpl. 2015;21:1410–1418.
  49. Carlessi R, Lemos NE, Dias AL, et al. Exendin-4 protects rat islets against loss of viability and function induced by brain death. Mol Cell Endocrinol. 2015;412:239–250.
  50. Hoeger S, Fontana J, Jarczyk J, et al. Vagal stimulation in brain dead donor rats decreases chronic allograft nephropathy in recipients. Nephrol Dial Transplant. 2014;29:544–549.
  51. de Ferrari GM, Schwartz PJ. Vagus nerve stimulation: From pre-clinical to clinical application: Challenges and future directions. Heart Fail Rev. 2011;16:195–203.
  52. Yurcisin BM, Davison TE, Bibbs SM, Collins BH, Stamler JS, Reynolds JD. Repletion of S-nitrosohemoglobin improves organ function and physiological status in swine after brain death. Ann Surg. 2013;257:971–977.
  53. Park ES, Son HW, Lee AR, et al. Inhaled nitric oxide for the brain dead donor with neurogenic pulmonary edema during anesthesia for organ donation: A case report. Korean J Anesthesiol. 2014;67:133–138.
  54. Cardini B, Watschinger K, Hermann M, et al. Crucial role for neuronal nitric oxide synthase in early microcirculatory derangement and recipient survival following murine pancreas transplantation. PLoS One. 2014;9:e112570.
  55. Koning AM, Frenay AR, Leuvenink HG, van Goor H. Hydrogen sulfide in renal physiology, disease and transplantation: The smell of renal protection. Nitric Oxide. 2015;46:37–49.
  56. George TJ, Arnaoutakis GJ, Beaty CA, et al. Inhaled hydrogen sulfide improves graft function in an experimental model of lung transplantation. J Surg Res. 2012;178:593–600.
  57. Lobb I, Davison M, Carter D, et al. Hydrogen sulfide treatment mitigates renal allograft ischemia-reperfusion injury during cold storage and improves early transplant kidney function and survival following allogeneic renal transplantation. J Urol. 2015;194:1806–1815.
  58. Balaban CL, Rodriguez JV, Tiribelli C, Guibert EE. The effect of a hydrogen sulfide releasing molecule (Na2S) on the cold storage of livers from cardiac dead donor rats: A study in an ex vivo model. Cryobiology. 2015;71:24–32.
  59. Nakao A, Toyoda Y. Application of carbon monoxide for transplantation. Curr Pharm Biotechnol. 2012;13:827–836.
  60. Ozaki KS, Kimura S, Murase N. Use of carbon monoxide in minimizing ischemia/reperfusion injury in transplantation. Transplant Rev (Orlando). 2012;26:125–139.
© Wroclaw Medical University